Compare Sociedad Quimica y Minera S.A. Common Stock (SQM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sociedad Quimica y Minera S.A. Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Sociedad Quimica y Minera S.A. Common Stock trades at $60.3 (market cap $17.61B), while Travere Therapeutics Inc. Common Stock trades at $54.58 (market cap $5.02B). The key difference: Sociedad Quimica y Minera S.A. Common Stock is far larger — about 3.5× Travere Therapeutics Inc. Common Stock's market cap, and Sociedad Quimica y Minera S.A. Common Stock pays a 3.93% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sociedad Quimica y Minera S.A. Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SQM | TVTX | |
|---|---|---|
Market Cap | $17.61B | $5.02B |
Volume | 996,244 | 2,060,842 |
Sector | Basic Materials | Health |
52-Week High | $95.31 | $67.52 |
52-Week Low | $42.39 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $18.47B | $5.15B |
Dividend Yield | 3.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SQM trades at $62.83, up 0.58% today, but technical indicators signal a bearish trend with strong selling pressure. The company delivered mixed Q2 2026 earnings, beating EPS estimates with $2.31 vs. $2.03 expected, while Q1 and Q4 2025 missed expectations. Valuation metrics appear attractive with P/E of 12.93 and EV/EBITDA of 7.09, supported by strong profitability margins including 42.17% gross margin and 23.78% ROE.
Despite near-term technical weakness, SQM's fundamentals remain solid with projected revenue growth to $6.7B in 2026 and net profit margin expansion to 20.62%. The consensus price target of $92.50 suggests 47% upside potential, though lithium price volatility and recent earnings misses present execution risks. Analyst sentiment is mixed with 31% Buy ratings versus 19% Sell recommendations.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sociedad Quimica y Minera S.A. Common Stock
SQM is a mining and chemical company operating in northern Chile. Its businesses include lithium, iodine, specialty plant nutrition, potassium, solar salts, and industrial chemicals.
Read more on SQM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
